All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Bookmark this article
During the 2023 Society of Hematologic Oncology (SOHO) annual congress, the MPN Hub was pleased to speak to Olatoyosi Sobulo Odenike, University of Chicago, Chicago, US. We asked, what are the management considerations for accelerated- and blast-phase MPN?
What are the management considerations for accelerated- and blast-phase MPN?
In the interview, Odenike outlines the characteristics of accelerated- and blast-phase MPN and highlights important management considerations, including key diagnostic and cytogenetic tests. Odenike concludes by discussing treatment goals and the increasing importance of clinical trials for this patient population.
Editorial theme | Progression in myeloproliferative neoplasms
This editorial theme article will discuss the clinical characteristics of progression of myeloproliferative neoplasms (MPN) and the risk factors associated with progression.
Single-cell analysis at ASH: Drivers of leukemic transformation
Around 10–20% of patients with myeloproliferative neoplasms (MPN) eventually develop secondary acute myeloid leukemia (sAML) and are faced with a poor prognosis. Certain mutations...
Subscribe to get the best content related to MPN delivered to your inbox